^{NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR ANY JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.}

SHOP APOTHEKE EUROPE grows by 39.7% in Q3.

• Preliminary sales growth of 39.7% to EUR 238.7 million in Q3 and of 38.1% to EUR 703.4 million YTD.
• Sales for the DACH Segment +33.8% and the International Segment +82.2% in Q3.
• Total number of active customers increased by 0.4 million to 5.9 million in Q3.

Venlo, 5 October 2020. SHOP APOTHEKE EUROPE N.V. increased its Q3 group sales by 39.7% to EUR 238.7 million according to preliminary calculations. For the first nine months, total sales were EUR 703.4 million, which translates into 38.1% growth compared to the first nine months of the previous year. SHOP APOTHEKE EUROPE gained 0.4 million active customers in Q3, reaching a total number of active customers of 5.9 million at the end of the quarter. Year to date, the total number of active customers increased by 1.2 million.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE: "We are again very proud of our achievements this quarter. We have continued to execute our strategy flawlessly, focusing on customer satisfaction and driving the implementation of our strategic initiatives at the same time."

In the DACH Segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE posted sales growth of 33.8% compared to the same quarter last year, resulting in sales of EUR 200.6 million this Q3. In the International Segment, which comprises the company's activities in France, Belgium, Italy and the Netherlands, SHOP APOTHEKE EUROPE increased its sales by 82.2% to EUR 38.1 million.

CFO Jasper Eenhorst comments: "We had another quarter with strong and fully organic growth of +39.7% and a high degree of customer satisfaction across all our markets. We are also very pleased that we have been promoted to the MDAX in September, which reflects the continuously increasing investor interest."

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the complete interim statement for the third quarter 2020 on 5 November 2020.

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of the leading and fastest-growing online pharmacies in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the areas of OTC, beauty and personal care products as well as prescription drugs is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE operates online pharmacies in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland at this moment. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 5.9 million active customers (at the end of Q3 2020) fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and is part of the MDAX index since 21 September 2020.

In addition to being traded on the Frankfurt stock exchange, SHOP APOTHEKE EUROPE'S convertible bonds (ISIN: DE000A19Y072) are also tradeable on the Dutch Euronext stock exchange, which operates the stock exchanges in Paris, Amsterdam, Brussels, Dublin, Oslo and Lisbon.
 

PRESS CONTACTS.

Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: presse@shop-apotheke.com

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: presse@shop-apotheke.com

 

DISCLAIMER.

This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of SHOP APOTHEKE EUROPE N.V. is not taking place.

Statements contained herein could constitute so-called "forward-looking statements". Forward-looking statements can be recognized by words such as "might," "will," "should," "plans," "anticipates," "anticipates," "estimates," "believes," "intends," "aims," "aim" or their negative form or corresponding modifications and comparable terms.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.